The addition of IACS‐010759 to standard T‐ALL chemotherapies further compounded this effect, and although a compensatory utilization of glutamine in TCA cycle fuelling was observed, the use of the glutaminase inhibitor CB‐839 synergistically reduced T‐ALL cell viability in all models [153]. This evidence concerns the gene GLS and acute lymphoblastic leukemia.